Clinical trials: High-risk Smoldering Multiple Myeloma
High Risk Smoldering Multiple Myeloma
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of CM-336, which is a BCMA/CD3 BiTE, in the treatment of high risk smoldering multiple myeloma.
- Trial name
- NCT06745687
- Testing
- CM336
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
High-risk Smoldering Multiple Myeloma, Multiple Myeloma
DARA RVD For High Risk SMM
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and…
- Trial name
- PRISM (NCT04775550)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Omar Nadeem, MD
Plasma Cell Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3 Part: To…
- Trial name
- NCT04270409
- Testing
- Isatuximab SAR650984, Lenalidomide, Dexamethasone
- Where
- 105 sites in United States, Australia and 22 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanofi